Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifinatamab deruxtecan - Daiichi Sankyo Company

Next Previous
Drug Profile

Ifinatamab deruxtecan - Daiichi Sankyo Company

Alternative Names: DS-7300; DS-7300a; I-DXd; MK-2400

Latest Information Update: 29 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Merck & Co
  • Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Small cell lung cancer
  • Phase III Oesophageal cancer; Prostate cancer; Squamous cell cancer
  • Phase II Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 21 Apr 2026 Daiichi Sankyo Company initiates expanded access programme for Ifinatamab deruxtecan for Small cell lung cancer (Late-stage disease, Second-line therapy) (NCT07535359)
  • 14 Apr 2026 Preregistration for Small cell lung cancer (Second-line therapy or greater, Metastatic disease) in USA (IV)
  • 14 Apr 2026 US FDA accepts NDA for Ifinatamab deruxtecan for Small cell lung cancer (Metastatic disease, Second-line therapy or greater) for review (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top